In a report released today, Brooks O’Neil from Lake Street maintained a Buy rating on P3 Health Partners (PIII – Research Report), with a price target of $4.50. The company’s shares closed yesterday at $0.75.
O’Neil covers the Healthcare sector, focusing on stocks such as Tandem Diabetes Care, ModivCare, and Augmedix. According to TipRanks, O’Neil has an average return of -2.8% and a 38.70% success rate on recommended stocks.
Currently, the analyst consensus on P3 Health Partners is a Moderate Buy with an average price target of $4.50.
Based on P3 Health Partners’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $288.35 million and a GAAP net loss of $13.3 million. In comparison, last year the company earned a revenue of $248.26 million and had a GAAP net loss of $11.17 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
P3 Health Partners (PIII) Company Description:
Foresight Acquisition Corp is a blank check company.
Read More on PIII:
- P3 Health Partners downgraded to Neutral from Buy at BTIG
- P3 Health Partners sees FY24 revenue $1.45B-$1.55B, consensus $1.42B
- P3 Health Partners reports Q4 EPS (22c), consensus (11c)
- P3 Health Partners Inc. (PIII) Q4 Earnings Cheat Sheet
- P3 Health Partners price target lowered to $4.50 from $9 at Lake Street
